Neurocritical Care

, Volume 19, Issue 2, pp 257–266

High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods

  • Sharon D. Yeatts
  • Yuko Y. Palesch
  • Claudia S. Moy
  • Magdy Selim
TAKE A CLOSER LOOK AT TRIALS
  • 461 Downloads

Abstract

Background

Hemoglobin degradation products, in particular iron, have been implicated in secondary neuronal injury following intracerebral hemorrhage (ICH). The iron chelator Deferoxamine Mesylate (DFO) exerts diverse neuroprotective effects, reduces perihematoma edema (PHE) and neuronal damage, and improves functional recovery after experimental ICH. We hypothesize that treatment with DFO could minimize neuronal injury and improve outcome in ICH patients. As a prelude to test this hypothesis, we conducted a Phase I, open-label study to determine the tolerability, safety, and maximum tolerated dose (MTD) of DFO in patients with ICH. Intravenous infusions of DFO in doses up to 62 mg/kg/day (up to a maximum of 6000 mg/day) were well-tolerated and did not seem to increase serious adverse events (SAEs) or mortality. We have initiated a multi-center, double-blind, randomized, placebo-controlled, Phase II clinical trial (High Dose Deferoxamine [HI-DEF] in Intracerebral Hemorrhage) to determine if it is futile to move DFO forward to Phase III efficacy evaluation.

Methods

We will randomize 324 subjects with spontaneous ICH to either DFO at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day) or saline placebo, given by intravenous infusion for 5 consecutive days. Treatment will be initiated within 24 hours after ICH symptom onset. All subjects will be followed for 3 months and will receive standard of care therapy while participating in the study. At 3 months, the proportion of DFO-treated subjects with a good clinical outcome, assessed by modified Rankin Scale, will be compared to the placebo proportion in a futility analysis.

Conclusions

The Hi-Def trial is expected to advance our understanding of the pathopgysiology of secondary neuronal injury in ICH and will provide a crucial “Go/No Go” signal as to whether a Phase III trial to investigate the efficacy of DFO is warranted.

Keywords

Intracerebral hemorrhage Deferoxamine Clinical trial Futility design 

References

  1. 1.
    Castillo J, Davalos A, Alvarez-Sabin J, Pumar JM, Leira R, Silva Y, Montaner J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002;58(4):624–9.PubMedCrossRefGoogle Scholar
  2. 2.
    He Y, Wan S, Hua Y, Keep RF, Xi G. Autophagy after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab. 2008;28(5):897–905.PubMedCrossRefGoogle Scholar
  3. 3.
    Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema after experimental intracerebral hemorrhage: role of hemoglobin degradation products. J Neurosurg. 2002;96(2):287–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Wagner KR, Sharp FR, Ardizzone TD, Lu A, Clark JF. Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood Flow Metab. 2003;23(6):629–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Selim M. Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke. 2009;40(3 Suppl):S90–1.PubMedCrossRefGoogle Scholar
  6. 6.
    Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. J Neurosurg. 2004;100(4):672–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Gu Y, Hua Y, Keep RF, Morgenstern LB, Xi G. Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke. 2009;40:2241–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G. Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke. 2009;40:1858–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Wan S, Hua Y, Keep RF, Hoff JT, Xi G. Deferoxamine reduces CSF free iron levels following intracerebral hemorrhage. Acta Neurochir Suppl. 2006;96:199–202.PubMedCrossRefGoogle Scholar
  10. 10.
    Messer JG, Cooney PT, Kipp DE. Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells. Bone. 2010;46(5):1408–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Ratan RR, Siddiq A, Aminova L, Langley B, McConoughey S, Karpisheva K, et al. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad Sci. 2008;1147:383–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Wan S, Zhan R, Zheng S, Hua Y, Xi G. Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron. Neurosci Res. 2009;63:100–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Tanji K, Imaizumi T, Matsumiya T, Itaya H, Fujimoto K, Cui X, et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta. 2001;1530(2–3):227–35.PubMedGoogle Scholar
  14. 14.
    Suri MF, Suarez JI, Rodrigue TC, Zaidat OO, Vazquez G, Wensel A, et al. Effect of treatment of elevated blood pressure on neurological deterioration in patients with acute intracerebral hemorrhage. Neurocrit Care. 2008;9(2):177–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, et al. Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011;42(11):3067–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Haley EC Jr, Thompson JL, Levin B, Davis S, Lees KR, Pittman JG, et al. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke. 2005;36(5):1006–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener HC, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke. 2007;38(8):2262–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer M, et al. Efficacy and safety of recombinant activated factor VII for acute ICH. N Engl J Med. 2008;358:2127–37.PubMedCrossRefGoogle Scholar
  20. 20.
    Chow S, Shao J, Wang H. Sample size calculations in clinical research. Boca Raton: CRC press; 2003.Google Scholar
  21. 21.
    Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 3rd ed. New York: Springer; 1998.CrossRefGoogle Scholar
  22. 22.
    McCarron MO, Hoffmann KL, DeLong DM, Gray L, Saunders AM, Alberts MJ. Intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes. Neurology. 1999;53(9):2176–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Sansing LH, Messe SR, Cucchiara BL, Lyden PD, Kasner SE. Anti-adrenergic medications and edema development after intracerebral hemorrhage. Neurocrit Care. 2011;14(3):395–400.PubMedCrossRefGoogle Scholar
  24. 24.
    Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, Ohno K. Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Suppl. 2003;86:445–8.PubMedGoogle Scholar
  25. 25.
    Zazulia AR, Diringer MN, Derdeyn CP, Powers WJ. Progression of mass effect after intracerebral hemorrhage. Stroke. 1999;30(6):1167–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Venkatasubramanian C, Mlynash M, Finley-Caulfield A, Eyngorn I, Kalimuthu R, Snider RW, Wijman CA. Natural history of perihematomal edema after intracerebral hemorrhage measured by serial magnetic resonance imaging. Stroke. 2011;42(1):73–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Macdonald RL, Marton LS, Andrus PK, Hall ED, Johns L, Sajdak M. Time course of production of hydroxyl free radical after subarachnoid hemorrhage in dogs. Life Sci. 2004;75(8):979–89.PubMedCrossRefGoogle Scholar
  28. 28.
    Wu J, Hua Y, Keep RF, Nakamura T, Hoff JT, Xi G. Iron and iron-handling proteins in the brain after intracerebral hemorrhage. Stroke. 2003;34(12):2964–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Palesch Y, Tilley B, Sackett D, Johnston K, Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005;36:2410–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Forstmeier W, Schielzeth H. Cryptic multiple hypotheses testing in linear models: overestimated effect sizes and the winner’s curse. Behav Ecol Sociobiol. 2011;65(1):47–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66(8):1175–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Russell MW, Joshi VA, Neumann PJ, Boulanger L, Menzin J. Predictors of hospital length of stay in patients with ICH. Neurology. 2006;67:1279–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Fisher M, Hanley DF, Howard G, Jauch EC. Warach S; STAIR Group. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38(2):245–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sharon D. Yeatts
    • 1
  • Yuko Y. Palesch
    • 1
  • Claudia S. Moy
    • 2
  • Magdy Selim
    • 3
  1. 1.Data Coordination Unit, Department of Public Health Sciences, College of MedicineMedical University of South CarolinaCharlestonUSA
  2. 2.National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaUSA
  3. 3.Stroke Division, Department of NeurologyBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations